[EN] ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE [FR] ARYL-HYDROXYÉTHYLAMINO-PYRIMIDINES ET TRIAZINES EN TANT QUE MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE
[EN] ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE [FR] ARYL-HYDROXYÉTHYLAMINO-PYRIMIDINES ET TRIAZINES EN TANT QUE MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE
4‐Iodopyrimidine Labeling Reveals Nuclear Translocation and Nuclease Activity for Both MIF and MIF2**
作者:Zhangping Xiao、Deng Chen、Fabian Mulder、Shanshan Song、Petra E. Wouden、Robbert H. Cool、Barbro N. Melgert、Gerrit J. Poelarends、Frank J. Dekker
DOI:10.1002/chem.202103030
日期:2022.1.3
based probe 8 for the selective labeling of MIF and MIF2. This enabled monitoring of the translocation of MIF2 from the cytoplasm to the nucleus upon methylnitronitrosoguanidine stimulation, which indicates a nucleaseactivity for MIF2 on human genomic DNA. Thus, we provide a tool for MIF and MIF2 localization study, as well as demonstrate a nucleaseactivity for MIF2.
Aryl - Hydroxyethylamino - Pyrimidines and Triazines as Modulators of Fatty Acid amide Hydrolase
申请人:Apodaca Richard
公开号:US20090264429A1
公开(公告)日:2009-10-22
Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.
Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
申请人:Apodaca Richard
公开号:US08598202B2
公开(公告)日:2013-12-03
Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.